Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An immunogenetic study in hypertrophic cardiomyopathy.

P Gregor1, E Ivasková, H Sajdlová

  • 12nd Department of Medicine, Charles University School of Medicine, Prague, Czechoslovakia.

Cor Et Vasa
|January 1, 1991
PubMed
Summary

Human Leukocyte Antigen (HLA) typing identified a significant association between HLA-B21 and severe hypertrophic cardiomyopathy, particularly obstructive forms. This finding may aid in early disease recognition and risk assessment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pacemaker reprogramming rarely needed after device replacement.

Herz·2017
Same author

THA and TKA in patients with cardiovascular disease: What makes the risk of perioperative bleeding?

Bratislavske lekarske listy·2017
Same author

Periprocedural antithrombotic therapy during various types of percutaneous cardiovascular interventions.

European heart journal. Cardiovascular pharmacotherapy·2016
Same author

Risk comparison of bleeding and ischemic perioperative complications after acute and elective orthopedic surgery in patients with cardiovascular disease.

Archives of orthopaedic and trauma surgery·2016
Same author

Perioperative cardiovascular complications versus perioperative bleeding in consecutive patients with known cardiac disease undergoing non-cardiac surgery. Focus on antithrombotic medication. The PRAGUE-14 registry.

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation·2014
Same author

Genetic testing in the management of relatives of patients with hypertrophic cardiomyopathy.

Folia biologica·2014

Area of Science:

  • Immunogenetics
  • Cardiology

Background:

  • Previous research on Human Leukocyte Antigen (HLA) associations with hypertrophic cardiomyopathy (HCM) has yielded inconsistent results.
  • Existing studies often lack sufficient patient numbers and fail to differentiate between HCM subtypes.

Purpose of the Study:

  • To investigate the association between specific HLA antigens and hypertrophic cardiomyopathy.
  • To explore potential links between HLA types and distinct clinical presentations of HCM.

Main Methods:

  • Detailed HLA typing of 60 Class I and II antigens was performed on 117 patients diagnosed with hypertrophic cardiomyopathy.
  • Statistical analyses, including relative risk and chi-square tests, were employed to identify significant associations.

Main Results:

Related Experiment Videos

  • A significantly higher frequency of the HLA-B21 antigen was observed in patients with obstructive HCM and those with advanced myocardial hypertrophy (wall thickness >30 mm).
  • Previous studies have linked HLA-B21 to other cardiovascular conditions, including ischemic heart disease and myocardial infarction in young individuals.

Conclusions:

  • HLA-B21 may serve as a potential genetic marker for specific, severe forms of hypertrophic cardiomyopathy.
  • HLA typing could assist in identifying atypical or severe presentations of HCM and assessing cardiovascular disease risk, particularly in populations like Czechoslovakia where HLA-B21 carriers face increased risk.